Stock ScreenerStock IdeasBiotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Stock ScreenerStock IdeasBiotech Breakthroughs
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Price | 1d % | 1w % | 1m % | 3m % | 6m % | 1y % | 3y % | 5y % | 10y % | 52-week High | 52-week Low | % off 52-week High | % off 52-week Low | Beta | Volume | Vol 1d % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CORT | CORCEPT THERAPEUTICS INC | $70.19 | -2.19% | -4.62% | 0.10% | -6.19% | -4.54% | 103.63% | 153.67% | 412.34% | 1,276.27% | $117.33 | $33.34 | 40.18% | 110.53% | 0.96 | 784,000 | 43.33% |
| TGTX | TG THERAPEUTICS INC | $27.92 | 0.69% | 2.95% | -25.39% | -20.18% | -9.96% | 10.84% | 299.43% | 18.56% | 82.84% | $46.48 | $21.11 | 39.93% | 32.26% | 1.90 | 1,676,000 | -28.92% |
| CRMD | CORMEDIX INC | $13.06 | -0.31% | 13.57% | 19.38% | 2.43% | 16.87% | 153.10% | 234.02% | 164.91% | -7.70% | $17.43 | $4.87 | 25.07% | 168.17% | 0.99 | 2,611,000 | 5.32% |
| GYRE | GYRE THERAPEUTICS INC | $7.53 | -4.08% | -0.40% | 6.06% | -32.22% | -37.97% | -35.97% | -74.77% | -90.60% | -99.78% | $19.00 | $6.11 | 60.37% | 23.24% | 1.25 | 68,000 | 7.26% |
| KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | $33.15 | -1.69% | 1.13% | 16.64% | 23.97% | 68.10% | 24.48% | 184.55% | 90.52% | N/A | $34.55 | $17.82 | 4.04% | 86.03% | 0.86 | 372,000 | -36.63% |
| KRYS | KRYSTAL BIOTECH INC | $143.96 | -1.60% | 0.24% | -2.79% | 8.82% | -18.28% | -27.55% | 88.75% | 201.61% | N/A | $207.84 | $122.80 | 30.74% | 17.23% | 1.35 | 175,000 | -29.15% |
| HALO | HALOZYME THERAPEUTICS INC | $69.98 | 1.48% | 9.28% | 25.14% | 31.31% | 21.14% | 13.35% | 65.59% | 146.93% | 274.02% | $70.70 | $42.01 | 1.02% | 66.58% | 0.86 | 3,002,000 | 61.92% |
| EXEL | EXELIXIS INC | $37.52 | -0.64% | -1.13% | -15.23% | -16.04% | 6.99% | 41.11% | 94.10% | 67.57% | 555.94% | $49.62 | $25.12 | 24.39% | 49.36% | 0.64 | 1,899,000 | -14.80% |
| RPRX | ROYALTY PHARMA PLC | $36.00 | 0.22% | 0.39% | 0.98% | 5.11% | 10.46% | 30.96% | -18.37% | -18.00% | N/A | $38.00 | $24.05 | 5.26% | 49.69% | 0.52 | 2,403,000 | 0.63% |
| AUPH | AURINIA PHARMACEUTICALS INC | $12.03 | -1.55% | 6.27% | 39.56% | 49.07% | 52.86% | 86.80% | 50.38% | -17.03% | 251.75% | $12.53 | $6.34 | 3.99% | 89.75% | 1.06 | 1,171,000 | -49.04% |
| INVA | INNOVIVA INC | $20.52 | -1.25% | 2.14% | 5.23% | 10.14% | 13.81% | 10.74% | 45.33% | 54.17% | 43.60% | $22.00 | $16.67 | 6.73% | 23.10% | 0.47 | 396,000 | -69.37% |
| VCEL | VERICEL CORP | $36.17 | -0.41% | -1.01% | 2.00% | -14.97% | -37.40% | -23.56% | 19.18% | 118.95% | 1,006.12% | $63.00 | $33.09 | 42.59% | 9.31% | 1.47 | 245,000 | -59.17% |
| ARGX | ARGENX SE | $656.89 | -0.67% | 3.03% | 16.03% | 13.63% | 2.62% | 25.32% | 71.40% | 177.03% | N/A | $696.21 | $510.06 | 5.65% | 28.79% | 0.67 | 324,000 | 5.19% |
| HRMY | HARMONY BIOSCIENCES HOLDINGS INC | $36.40 | -0.03% | 2.62% | 3.26% | 1.36% | 3.06% | -0.11% | -22.68% | -1.65% | N/A | $41.61 | $26.47 | 12.52% | 37.51% | 0.85 | 418,000 | -12.73% |
| INCY | INCYTE CORP | $85.46 | 0.64% | 4.72% | 26.83% | 33.93% | 21.81% | 35.09% | 14.65% | -11.23% | -23.97% | $87.24 | $53.56 | 2.04% | 59.56% | 0.59 | 1,824,000 | 4.77% |
| ADMA | ADMA BIOLOGICS INC | $17.44 | -1.08% | 4.06% | 1.81% | -13.62% | 8.53% | -4.28% | 583.92% | 516.25% | 84.75% | $25.67 | $13.50 | 32.06% | 29.19% | 1.13 | 2,608,000 | -10.01% |
| MNKD | MANNKIND CORP | $3.96 | 3.94% | 8.20% | 3.66% | -11.41% | -28.13% | -25.98% | 1.02% | 110.64% | -80.15% | $7.63 | $3.38 | 48.10% | 17.13% | 1.11 | 3,135,000 | 40.77% |
| ATRA | ATARA BIOTHERAPEUTICS INC | $11.48 | 0.00% | -0.52% | -0.17% | 70.58% | 47.75% | 59.67% | -89.68% | -96.42% | -99.02% | $18.71 | $5.01 | 38.63% | 129.37% | 1.85 | 35,200 | -54.87% |
| MDXG | MIMEDX GROUP INC | $7.19 | 0.00% | -0.55% | 8.12% | 0.42% | -10.79% | 9.77% | 83.42% | 5.43% | -22.77% | $10.14 | $5.47 | 29.09% | 31.44% | 1.21 | 585,000 | 28.85% |
| TECH | BIO-TECHNE CORP | $54.87 | 2.96% | 3.86% | 9.15% | 11.34% | -16.61% | -26.83% | -38.14% | -15.60% | 108.41% | $80.95 | $46.01 | 32.22% | 19.26% | 1.17 | 1,618,000 | 29.23% |
| VCYT | VERACYTE INC | $29.57 | -1.66% | 2.78% | 28.40% | 1.97% | -29.78% | -8.57% | 36.27% | -14.54% | 230.39% | $47.32 | $22.61 | 37.51% | 30.78% | 1.93 | 974,000 | 53.63% |
| NVO | NOVO NORDISK A S | $54.78 | 1.92% | 10.04% | -15.62% | -18.26% | -34.32% | -59.50% | 4.79% | 64.43% | 87.35% | $139.74 | $45.05 | 60.80% | 21.60% | 0.61 | 25,887,000 | -16.10% |
| BMRN | BIOMARIN PHARMACEUTICAL INC | $57.31 | -0.23% | 0.79% | 1.33% | -3.53% | -12.65% | -38.22% | -38.27% | -25.29% | -57.77% | $94.64 | $52.93 | 39.44% | 8.28% | 0.75 | 1,434,000 | -15.20% |
| NAGE | NIAGEN BIOSCIENCE INC | $9.63 | -4.84% | -6.14% | -0.52% | -11.89% | 64.90% | 194.50% | 517.31% | 81.70% | 165.29% | $14.69 | $3.10 | 34.45% | 210.65% | 1.29 | 742,000 | -23.19% |
| CPRX | CATALYST PHARMACEUTICALS INC | $20.25 | 0.10% | -0.44% | -3.62% | -17.78% | -10.12% | 1.30% | 43.62% | 459.39% | 425.97% | $26.58 | $19.00 | 23.81% | 6.58% | 1.05 | 1,023,000 | -27.34% |
| GMAB | GENMAB A | $23.82 | 1.71% | 8.92% | 9.82% | 18.04% | 8.42% | -14.16% | -33.63% | -35.13% | 154.81% | $27.94 | $17.24 | 14.75% | 38.21% | 0.73 | 1,002,000 | 21.75% |
| VRTX | VERTEX PHARMACEUTICALS INC | $390.76 | 0.23% | 0.77% | -14.77% | -11.32% | -17.17% | -19.93% | 30.67% | 44.69% | 176.19% | $519.88 | $362.50 | 24.84% | 7.80% | 0.60 | 1,463,000 | 10.25% |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.